专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2023019129A1 BIOMARKERS FOR CD40 AGONIST THERAPY 审中-公开
公开(公告)号：WO2023019129A1
公开(公告)日：2023-02-16
申请号：PCT/US2022/074696
申请日：2022-08-09
申请人： APEXIGEN, INC.
发明人： YANG, Xiaodong , KATLINSKAYA, Yuliya , FILBERT, Erin L.
IPC分类号： A61P35/00 , C07K16/28
摘要： Provided are biomarkers and other characteristics for predicting tumor responsiveness to CD40 agonist therapy, and related kits, compositions, and methods of treating melanomas, including PD-1 refractory melanomas.

2. 发明申请

WO2018237287A1 ANTI-VISTA ANTIBODIES AND METHODS OF USE 审中-公开
公开(公告)号：WO2018237287A1
公开(公告)日：2018-12-27
申请号：PCT/US2018/039036
申请日：2018-06-22
申请人： APEXIGEN, INC.
发明人： FILBERT, Erin L. , TAN, Christine , BJÖRCK, Pia , YANG, Xiaodong
IPC分类号： C07K16/18 , A61K38/21 , A61K39/395
摘要： Provided are anti-VISTA monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of a variety of inflammatory, oncological, and infectious diseases.

3. 发明申请

WO2018085533A2 ANTI-CD40 ANTIBODIES IN COMBINATION AND METHODS OF USE 审中-公开
标题翻译：抗CD40抗体的组合和使用方法
公开(公告)号：WO2018085533A2
公开(公告)日：2018-05-11
申请号：PCT/US2017/059710
申请日：2017-11-02
申请人： APEXIGEN, INC.
发明人： BJÖRCK, Pia , FILBERT, Erin L. , YANG, Xiaodong
IPC分类号： A61K39/395
摘要： The present invention provides methods that utilize an agonistic anti-CD40 antibody in combination with another immune modulating agent, such as an immune checkpoint inhibitor (e.g., PD-1 inhibitor, PD-L1 inhibitor, CTLA-4 inhibitor, or VISTA inhibitor) and/or an innate immunity activator (e.g., TLR-4 agonist) and related compositions. The high affinity anti-CD40 antibody combinations may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases. In particular, combinations of the anti-CD40 antibody APX005M with an immune checkpoint inhibitor or an innate immunity activator are disclosed.
摘要翻译：本发明提供了将激动性抗-CD40抗体与另一种免疫调节剂例如免疫检查点抑制剂（例如，PD-1抑制剂，PD-L1抑制剂，CTLA- 4抑制剂或VISTA抑制剂）和/或先天免疫激活剂（例如TLR-4激动剂）和相关组合物。高亲和力抗-CD40抗体组合可以用于治疗癌症和其他疾病的各种治疗方法中的任何一种。具体而言，公开了抗CD40抗体APX005M与免疫检查点抑制剂或先天免疫激活剂的组合。

4. 发明申请

WO2021174127A1 ANTI-SIRPA ANTIBODIES AND METHODS OF USE 审中-公开
公开(公告)号：WO2021174127A1
公开(公告)日：2021-09-02
申请号：PCT/US2021/020097
申请日：2021-02-26
申请人： APEXIGEN, INC.
发明人： SRIVASTAVA, Minu K , JALGAONKAR, Swati , TAN, Christine , HUANG, George , BAHJAT, Rena , YANG, Xiaodong , FILBERT, Erin L. , ALVARADO, Ryan , KRISHNAN, Sushma
IPC分类号： C07K16/28 , C07K16/40 , C12N15/85
摘要： Provided are anti-signal regulatory protein α (SIRPα) antibodies and related compositions, which may be used in any of a variety of therapeutic or diagnostic methods, including the treatment or diagnosis of oncological diseases and others.

5. 发明申请

WO2021055253A ANTI-TNFR2 ANTIBODIES AND METHODS OF USE 审中-公开
公开(公告)号：WO2021055253A
公开(公告)日：2021-03-25
申请号：PCT/US2020/050515
申请日：2020-09-11
申请人： APEXIGEN, INC. [US]/[US]
发明人： FILBERT, Erin L. , KRISHNAN, Sushma , TAN, Christine , BAHJAT, Rena , YANG, Xiaodong , ALVARADO, Ryan
IPC分类号： A61K39/395 , A61P35/00 , C07K16/28 , C07K16/30 , A61K2039/505 , C07K16/2878 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/732 , C07K2317/76 , C07K2317/92
摘要： Provided are anti-tumor necrosis factor receptor 2 (TNFR2) antibodies and related compositions, which may be used in any of a variety of therapeutic or diagnostic methods, including the treatment or diagnosis of oncological diseases, inflammatory and/or autoimmune diseases, and others. In some embodiments, the isolated antibody, or antigen-binding fragment thereof, does not substantially bind to TNFR1, herpesvirus entry mediator (HVEM), CD40, death receptor 6 (DR6), and/or osteoprotegerin (OPG).

6. 发明申请

WO2019143837A1 ANTI-PD-L1 ANTIBODIES AND METHODS OF USE 审中-公开
公开(公告)号：WO2019143837A1
公开(公告)日：2019-07-25
申请号：PCT/US2019/014041
申请日：2019-01-17
申请人： APEXIGEN, INC.
发明人： BJÖRCK, Pia , TAN, Christine , FILBERT, Erin L. , YANG, Xiaodong
IPC分类号： C07K16/28 , C07K16/30 , A61K39/395
摘要： Provided are anti-programmed death-ligand 1 (PD-L1) monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of inflammatory and oncological diseases. Specifically, high affinity, humanized anti-PD-L1 antibodies are provided.

7. 发明申请

WO2018085533A3 ANTI-CD40 ANTIBODIES IN COMBINATION AND METHODS OF USE 审中-公开
公开(公告)号：WO2018085533A3
公开(公告)日：2018-05-11
申请号：PCT/US2017/059710
申请日：2017-11-02
申请人： APEXIGEN, INC.
发明人： BJÖRCK, Pia , FILBERT, Erin L. , YANG, Xiaodong
IPC分类号： A61K39/395 , A61K39/00 , C07K16/28 , C07K16/30
摘要： The present invention provides methods that utilize an agonistic anti-CD40 antibody in combination with another immune modulating agent, such as an immune checkpoint inhibitor (e.g., PD-1 inhibitor, PD-L1 inhibitor, CTLA-4 inhibitor, or VISTA inhibitor) and/or an innate immunity activator (e.g., TLR-4 agonist) and related compositions. The high affinity anti-CD40 antibody combinations may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases. In particular, combinations of the anti-CD40 antibody APX005M with an immune checkpoint inhibitor or an innate immunity activator are disclosed.

8. 发明申请

WO2012118813A3 ANTI-IL-6 RECEPTOR ANTIBODIES AND METHODS OF USE 审中-公开
标题翻译：抗IL-6受体抗体和使用方法
公开(公告)号：WO2012118813A3
公开(公告)日：2012-11-08
申请号：PCT/US2012026954
申请日：2012-02-28
申请人： APEXIGEN INC , LEE SUM WAI PIERRE , KE YAOHUANG , ZHANG YONGKE
发明人： LEE SUM WAI PIERRE , KE YAOHUANG , ZHANG YONGKE
IPC分类号： C07K16/28 , A61K39/395 , A61P29/00 , A61P35/00 , C12N15/13
CPC分类号： C07K16/2866 , C07K2317/24 , C07K2317/33 , C07K2317/522 , C07K2317/54 , C07K2317/55 , C07K2317/76 , C07K2317/92
摘要： The present invention provides anti-IL-6R monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of rheumatoid arthritis and other diseases.
摘要翻译：本发明提供了抗IL-6R单克隆抗体和相关组合物，其可用于治疗类风湿性关节炎和其他疾病的各种治疗方法中的任一种。

9. 发明申请

WO2012149356A3 ANTI-CD40 ANTIBODIES AND METHODS OF USE 审中-公开
公开(公告)号：WO2012149356A3
公开(公告)日：2012-11-01
申请号：PCT/US2012/035502
申请日：2012-04-27
申请人： APEXIGEN, INC. , ZHANG, Yongke , YU, Guo-Liang , ZHU, Weimin
发明人： ZHANG, Yongke , YU, Guo-Liang , ZHU, Weimin
IPC分类号： C07K16/28 , C12N15/13 , A61K39/395 , A61P35/00
摘要： The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases.

10. 发明申请

WO2014159430A1 ANTI-RANKL ANTIBODIES AND METHODS OF USE 审中-公开
标题翻译：抗RANKL抗体及其使用方法
公开(公告)号：WO2014159430A1
公开(公告)日：2014-10-02
申请号：PCT/US2014/023623
申请日：2014-03-11
申请人： APEXIGEN, INC.
发明人： ZHANG, Yongke , YANG, Xiaodong , YU, Guo-Liang , ZHU, Weimin
IPC分类号： C07K16/24 , A61K39/395
CPC分类号： C07K16/2875 , A61K2039/505 , C07K2317/24 , C07K2317/33 , C07K2317/54 , C07K2317/76 , C07K2317/92
摘要： The present invention provides anti-RANKL monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of rheumatoid arthritis and other diseases.
摘要翻译：本发明提供抗RANKL单克隆抗体和相关组合物，其可用于治疗类风湿性关节炎和其它疾病的各种治疗方法中的任何一种。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式